Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer
Molecular Oncology · 2025-09 · 19 (9) · 2730-2749
DOI: 10.1002/1878-0261.70035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 21.04.2025. Verfasst von Liyun Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Thymosin, Lung Neoplasms, Protein Precursors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Taipei Medical University.
Abstract (Originalsprache)
Elevated expression of prothymosin α (ProT) is frequently observed in cancers, but the underlying molecular mechanism remains poorly understood. Here, we report the clinical relevance of ProT expression and its correlation with lung cancer progression. We have shown that ProT was highly expressed in early‐stage lung cancer, exhibiting nuclear localization; on the contrary, a loss of nuclear ProT expression was detected in late‐stage tumor specimens. Furthermore, the expression of nuclear ProT impaired lung cancer cell migration, suppressed TGF‐β‐induced epithelial‐to‐mesenchymal transition (EMT)‐associated transcription factor expression, and inhibited in vivo tumor metastasis. The suppressive effect of ProT was further found to trigger Smad7 acetylation‐dependent deregulation of TGF‐β signaling. ProT enhanced Smad7 stability by promoting its lysine acetylation, thereby competing with the binding of Smad2 to the SNAI1 , TWIST1 , and ZEB1 promoters. Eventually, the binding of Smad7 in the presence of ProT resulted in reduced expression of the EMT transcription factors, leading to the inhibition of TGF‐β‐induced EMT and tumor metastasis. Collectively, this study unravels the role of ProT in lung cancer progression and highlights the potential of nuclear ProT as an indicator for monitoring tumor development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO, USA.
- Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Tong Yuan Diabetes Center, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Thoracic Division, Department of Surgery, Ditmanson Medical Foundation Chiayi Christian Hospital, Taiwan.
- Institute of Molecular Biology, National Chung Cheng University, Chiayi, Taiwan.
ORCID-Profile: Bing-Hua Su
Förderung
- National Science and Technology Council
- Taipei Medical University
Zitieren
APA
Chen, L., Wang, C. T., Chang, J. M., Shiau, A. L., Shieh, G. S., Tseng, Y. L., Yen, Y. T., Huang, T. H., Cheng, L. H., Wu, Y. C., Wu, C. L., Su, B. H., & Wu, P. (2025). Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer. Molecular Oncology, 19(9), 2730-2749. https://doi.org/10.1002/1878-0261.70035
Vancouver
Chen L, Wang CT, Chang JM, Shiau AL, Shieh GS, Tseng YL, et al. Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer. Molecular Oncology. 2025;19(9):2730-2749. doi:10.1002/1878-0261.70035
BibTeX
@article{Chen2025,
author = {Chen, Liyun and Wang, Chung-Teng and Chang, Jia-Ming and Shiau, Ai-Li and Shieh, Gia-Shing and Tseng, Yau-Lin and Yen, Yi-Ting and Huang, Tang-Hsiu and Cheng, Li-Hsin and Wu, Yu-Chih and Wu, Chao-Liang and Su, Bing-Hua and Wu, Pensee},
title = {Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer},
journal = {Molecular Oncology},
year = {2025},
volume = {19},
number = {9},
pages = {2730--2749},
doi = {10.1002/1878-0261.70035}
}
EUVIMED